While not currently a standard pemphigus therapy, INE effectively reduced Dsg1 and Dsg3 levels to normal, resolved symptoms, reduced Pemphigus Disease Activity Index scores, and allowed prednisone tapering to 5 mg per day (Fig 3, A and B). The gene discussed is DSG3; the disease is pemphigus.